Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Files An 8-K Submission of Matters to a Vote of Security Holders
On June 11, 2019, Eiger BioPharmaceuticals, Inc. (the Company) held its annual meeting of stockholders (the Annual Meeting). The following is a brief description of each matter voted upon at the Annual Meeting, as well as the number of votes cast for or against each matter and the number of abstentions and broker non-votes with respect to each matter. A more complete description of each matter is described in more detail in the Companys definitive proxy statement filed with the Securities and Exchange Commission on April 26, 2019.
Proposal 1Election of Directors
|15,122,221 || ||33,965 || ||749,012|
The Companys stockholders ratified the selection by the Audit Committee of the Board of Directors of KPMG LLP as the Companys independent registered public accounting firm for the fiscal year ending December 31, 2019.
No other matters were submitted for stockholder action.
About Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR)
Eiger BioPharmaceuticals, Inc., formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe hypoglycemia, and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema. Lonafarnib is an orally active inhibitor of farnesyl transferase that inhibits the prenylation step of HDV replication inside liver cells and blocks the ability of the virus to multiply. It is conducting over three Phase II clinical trials, which include LOnafarnib With and without Ritonavir (LOWR) HDV-2 (Ankara, Turkey), LOWR HDV-3 (NIH) and LOWR HDV-4 (Hannover, Germany). Exendin is in Phase II clinical studies for the treatment of hypoglycemia associated with bariatric surgery. Ubenimex is in Phase II clinical studies for the treatment of PAH and lymphedema.
An ad to help with our costs